We are live on ! Find out more
PDM

Penn Davis McFarland Portfolio holdings

AUM $1.12B
1-Year Est. Return 32.35%
This Fund
S&P 500
This Quarter Est. Return
+11.33%
1 Year Est. Return
+32.35%
3 Year Est. Return
+86.8%
5 Year Est. Return
+114.42%
10 Year Est. Return
+392.43%
AUM
$337M
AUM Growth
+$17.5M
Cap. Flow
-$10.1M
Cap. Flow %
-3%
Top 10 Hldgs %
67.81%
Holding
53
New
9
Increased
13
Reduced
16
Closed
4

Top Buys

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$11.6M
2
UNH icon
UnitedHealth
UNH
+$5.14M
3
ATVI
Activision Blizzard
ATVI
+$3.68M
4
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$936K
5
BMY.RT
Bristol-Myers Squibb Company Contingent Value Rights
BMY.RT
+$532K

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$20.9M
2
GILD icon
Gilead Sciences
GILD
+$7.58M
3
NLSN
Nielsen Holdings plc
NLSN
+$2.28M
4
GOOG icon
Alphabet (Google) Class C
GOOG
+$529K
5
NBL
Noble Energy, Inc.
NBL
+$410K

Sector Composition

Rank Sector Weight
1 Technology 27.75%
2 Energy 17.25%
3 Communication Services 16.89%
4 Healthcare 13.49%
5 Industrials 8.44%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WES icon
51
Western Midstream Partners
WES
$19.3B
– –
-8,388
Closed -$209K
CELG
52
DELISTED
Celgene Corp
CELG
– –
-210,502
Closed -$20.9M
1 2
3

Similar funds

EC
Estate Counselors Thiensville, Wisconsin $1.12B AUM 20.13% 1-Year Est. Return
FBFS
First Business Financial Services Madison, Wisconsin $1.12B AUM 22.16% 1-Year Est. Return
JAFL
Jay A. Fishman Ltd Troy, Michigan $1.12B AUM 32.75% 1-Year Est. Return
SL
Salomon & Ludwin Richmond, Virginia $1.12B AUM 14.38% 1-Year Est. Return
PTC
Private Trust Company Cleveland, Ohio $1.12B AUM 21.35% 1-Year Est. Return
CT
Caldwell Trust Venice, Florida $1.12B AUM 21.31% 1-Year Est. Return
DFCM
Dark Forest Capital Management San Juan, Puerto Rico $1.13B AUM 18.74% 1-Year Est. Return
PL
Parkwood LLC Cleveland, Ohio $1.13B AUM 32.89% 1-Year Est. Return

Penn Davis McFarland's Q4 2019 Portfolio in Review

As of Q4 2019, Penn Davis McFarland held 53 positions worth $337M, up 5.5% from $320M the previous quarter. Its ten largest holdings account for 68% of the portfolio.

Penn Davis McFarland's Q4 2019 filing shows 9 new, 13 increased, 16 reduced and 4 closed positions. Its largest new stake was Reata Pharmaceuticals, Inc. Class A Common Stock: 5,131 shares worth $1.05M. The largest sale was Celgene Corp, an estimated $20.9M.

By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 24% a quarter earlier, followed by Energy and Communication Services.

  • Penn Davis McFarland's largest Q4 2019 buy was Reata Pharmaceuticals, Inc. Class A Common Stock: 5,131 shares worth $1.05M.
  • Penn Davis McFarland added most to Bristol-Myers Squibb in Q4 2019, an estimated $11.6M increase.
  • Penn Davis McFarland's biggest Q4 2019 reduction was Gilead Sciences, cutting an estimated $7.58M.
  • Penn Davis McFarland fully exited Celgene Corp in Q4 2019, selling an estimated $20.9M.
  • Penn Davis McFarland's ten largest holdings make up 68% of its $337M portfolio in Q4 2019.
  • Penn Davis McFarland opened 9 new positions and closed 4 in Q4 2019.
  • Penn Davis McFarland's portfolio value rose 5.5% quarter-over-quarter to $337M.

Based on Penn Davis McFarland's 13F filing for Q4 2019, filed 17 Jan 2020.